摘要
目的观察冻干重组人脑利钠肽治疗心力衰竭患者的临床疗效。方法选取自2013年9月至2015年9月于大连市友谊医院收治的的心力衰竭病例40例,采用信封法随机分为试验组和对照组,对照组20例,采用常规抗心力衰竭治疗的方法,试验组20例,在对照组基础采用冻干重组人脑利钠肽,观察患者左心射血分数、心功能和BNP情况。结果试验组优于对照组,有统计学差异(P<0.05)。结论冻干重组人脑利钠肽可以改善心力衰竭患者心功能,治疗心力衰竭患者安全有效,值得推广。
Objective To observe the clinical efficacy of Lyophilized Recombinant Human Brain Natriuretic Peptide therapy in patients with heart failure. Methods Since September 2013 to September 2015 in Dalian Friendship Hospital of heart failure cases in 40 cases, the envelopes were randomly divided into experimental group and control group, 20 cases in the control group, the routine anti heart failure treatment method of 20 cases of test group and in the control group based on the use of freeze-dried group human brain natriuretic peptide were observed in patients with left heart ejection fraction, heart function and BNP situation. Results The experimental group was better than the control group, with statistical difference（P 〈0.05）. Conclusion The lyophilized recombinant human brain natriuretic peptide can improve heart function in patients with congestive heart failure and treatment in patients with heart failure safe and effective, and is worth popularizing.
出处
《中国医药指南》
2017年第4期5-6,共2页
Guide of China Medicine
关键词
心力衰竭
冻干重组人脑利钠肽
Heart failure
Lyophilized Recombinant Human Brain Natriuretic Peptide
